Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Agreement on Phase 3 Trial Protocol of OSE Pharma's OSE-2101 From the FDA and EMA


News provided by

OSE Pharma

23 Jun, 2014, 17:10 GMT

Share this article

Share toX

Share this article

Share toX

PARIS, June 23, 2014 /PRNewswire/ --

OSE Pharma SA receives a positive agreement to initiate a Phase 3 clinical trial with OSE-2101, a therapeutic cancer vaccine for non-small cell lung cancer (NSCLC) 

OSE Pharma SA, a European cancer immunotherapy company with a specific T cytotoxic technology, today announced that it has received positive feedback from an end of Phase 2 / Pre-Phase 3 meeting with the U.S. Food and Drug Administration (FDA) and Scientific Advice from the European Medicines Agency's (EMA).

OSE-2101 is a multi-epitope therapeutic cancer vaccine for the treatment of advanced NSCLC (non-small cell lung cancer) in HLA-A2 positive patients who have failed first line therapy. Since February 2013, OSE-2101 has been granted orphan drug status by the FDA for the treatment of NSCLC in patients expressing HLA-A2.

OSE PHARMA plans to initiate in early 2015 a Phase 3 trial with OSE-2101 

The pivotal Phase 3 trial with OSE-2101 will be conducted in patients with advanced stage IIIb invasive or metastatic stage IV NSCLC patients who express the HLA-A2 receptor (45% of the NSCLC population).  The study, which plans to recruit 500 patients in the US and Europe, will compare OSE-2101 versus standard of care, either docetaxel or pemetrexed, two chemotherapeutic agents which are approved as second line treatments in this patient population. The primary end-point of the trial will be overall survival (OS). The study's secondary end-points include progression free survival (PFS), safety, quality of life and overall response rate (ORR). All of the key parameters of the pivotal Phase 3 trial have been discussed in detail with FDA and EMA.

OSE-2101, is a patented combination of ten epitopes (synthetic peptides) optimized from five tumor antigens. These epitopes have been selected based on their ability to generate specific cytotoxic T-cell responses against these antigens. The presence of these five tumor antigens (HER-2/neu, p53, CEA, MAGE-2 and MAGE- 3) and expression of the HLA-A2 receptor are poor prognosis factors in several types of cancers. There is considerable medical need for a well-tolerated treatment that prolongs overall survival and increases progression free survival.

"I am glad about this simultaneous positive response from both agencies, the FDA and the EMA, for the pivotal Phase 3 with OSE-2101 in a severe cancer patient population. We now have a clear plan for advancing what we believe is an exciting new cancer immunotherapy. Given my personal involvement in the development of OSE-2101, I am confident that this multi-epitope therapeutic vaccine will provide important benefits to patients with cancers," stated Emile Loria, Chairman, OSE Pharma."

"We are actively preparing for the start of the OSE-2101 Phase 3 study both in terms of the clinical trial logistics and the manufacturing of the product needed to conduct this trial planned to begin in the first semester of 2015," added Dominique Costantini, CEO, OSE Pharma.

Positive Phase 2 Results  

An US Phase 2 multicenter study with OSE-2101 showed that the therapeutic cancer vaccine was effective, increasing the specific T cytotoxic response and the survival while being well tolerated.

Median survival for the OSE-2101 treated patients in this Phase 2 study was 17.3 months compared to 12.0 months for patients in the HLA-A2-negative observation group. Of the patients treated with OSE-2101, 91% elicited positive immune cytotoxic T cell response to one or more epitopes. The length of survival of patients treated with OSE-2101 was correlated significantly with the breadth of the individual patient's immune response (p<0.001).

This study recruited a total of 135 NSCLC patients, 64 HLA-A2 positive dosed with OSE-2101 and 71 HLA-A2 negative which formed the concurrent observation control group (providing information on survival at one year). All of the patients had advanced disease (invasive stage IIIb or metastatic stage IV) and were metastatic for 67% of them. The patients were previously highly treated with 65.5% of patients having received more than 2 previous lines.

About OSE Pharma 

OSE Pharma is a European cancer immunotherapy company with a specific T cytotoxic technology, focused on developing multi-epitopes therapeutic cancer vaccines.

OSE Pharma's lead product, OSE-2101 is about to enter a pivotal Phase 3 study in patients with non-small cell lung cancer (NSCLC), is ready for Phase 2 development in other cancer indications (ovarian, colon, breast, prostate) and is a suitable candidate for immune combination therapy.

OSE-2101 targets five tumor associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. OSE-2101 contains ten optimized epitopes, derived from these five tumor antigens, which generate strong specific T cytotoxic responses that lead to the body's immune system killing tumor cells expressing the tumor antigens.  

Since 2012 OSE Pharma is managed by Emile Loria and Dominique Costantini, two experienced biotech entrepreneurs, and is established in Paris - Hospital Cochin France. In 2014, the company completed the acquisition of OSE-2101 technology assets, worldwide rights and related know-how.  The decision to acquire OSE-2101 was based on Dr Emile Loria's previous experience as CEO of Epimmune, responsible for initiating the clinical development of this novel cancer immunotherapy product.

Lung cancer  

Lung cancer is the leading cause of cancer death in the world. More people die of lung cancer than of colon, breast and prostate cancers combined. According to the epidemiology site of Globocan (IARC 2012), lung cancer (non-small cell, NSCLC, and small cell type) affects more than 1.58 million patients a year, with around 1.39 million deaths annually and around 600,000 in Europe (27) (288 000) the U.S (214 000), and Japan (141 000). About 85 to 88% of all lung cancers are of the non-small cell type. The majority of patients are at advanced stage disease at diagnosis: stage III invasive or stage IV metastatic. Despite aggressive treatments, the five-year relative survival rates are about 1% for patients with metastatic disease (stage IV).

Press Contacts

http://www.theralpha.com

OSE Pharma sa
Dominique Costantini, Directeur Général
dominique.costantini@osepharma.com
Mob : +33-6-13-20-77-49

Alexis Peyroles, DAF
Alexis.peyroles@osepharma.com
Mob : +33-6-11-51-19-77

HB ComCorp
Florence Portejoie
+33-1-58-18-32-58 / +33-6-88-84-81-74
fportejoie@comcorp.fr

Anne Hardy
+33-1-58-18-32-51 / +33-6-13-56-23-96
ahardy@comcorp.fr

Citigate Dewe Rogerson
Laurence Bault
+33-1-53-32-84-78
laurence.bault@citigate.fr

Lucie Larguier
+33-1-53-32-84-75
lucie.larguier@citigate.fr

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.